Systematic Financial Management LP Has $13.62 Million Stock Holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Share on StockTwits

Systematic Financial Management LP increased its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 0.8% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 106,278 shares of the specialty pharmaceutical company’s stock after purchasing an additional 794 shares during the period. Systematic Financial Management LP owned approximately 0.19% of Jazz Pharmaceuticals worth $13,618,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of JAZZ. Machina Capital S.A.S. bought a new stake in Jazz Pharmaceuticals during the second quarter worth about $29,000. Signaturefd LLC grew its stake in Jazz Pharmaceuticals by 56.3% during the second quarter. Signaturefd LLC now owns 200 shares of the specialty pharmaceutical company’s stock worth $29,000 after buying an additional 72 shares during the last quarter. Captrust Financial Advisors grew its stake in Jazz Pharmaceuticals by 120.0% during the second quarter. Captrust Financial Advisors now owns 220 shares of the specialty pharmaceutical company’s stock worth $31,000 after buying an additional 120 shares during the last quarter. Stonebridge Capital Advisors LLC bought a new stake in Jazz Pharmaceuticals during the second quarter worth about $37,000. Finally, AdvisorNet Financial Inc bought a new stake in Jazz Pharmaceuticals during the third quarter worth about $37,000. 87.74% of the stock is owned by hedge funds and other institutional investors.

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 500 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $130.00, for a total value of $65,000.00. Following the transaction, the chief executive officer now directly owns 311,855 shares of the company’s stock, valued at $40,541,150. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 4.30% of the stock is currently owned by company insiders.

Several analysts have weighed in on the stock. TheStreet cut shares of Jazz Pharmaceuticals from a “b-” rating to a “c+” rating in a research note on Friday, October 18th. BidaskClub cut shares of Jazz Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, October 11th. Oppenheimer set a $176.00 price objective on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, September 26th. Zacks Investment Research cut shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating and set a $138.00 price objective on the stock. in a research note on Friday, September 13th. Finally, Barclays reissued a “buy” rating and set a $182.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, November 7th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $165.71.

Shares of JAZZ traded up $1.45 during mid-day trading on Tuesday, hitting $132.33. 406,400 shares of the company traded hands, compared to its average volume of 550,702. Jazz Pharmaceuticals PLC has a one year low of $113.52 and a one year high of $154.44. The company has a current ratio of 3.89, a quick ratio of 3.71 and a debt-to-equity ratio of 0.56. The business has a 50-day moving average of $124.79 and a 200 day moving average of $131.73. The stock has a market capitalization of $7.36 billion, a price-to-earnings ratio of 10.81, a PEG ratio of 1.02 and a beta of 1.09.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Tuesday, November 5th. The specialty pharmaceutical company reported $4.10 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.19 by $0.91. Jazz Pharmaceuticals had a net margin of 29.61% and a return on equity of 27.99%. The business had revenue of $537.70 million for the quarter, compared to analysts’ expectations of $523.92 million. During the same period in the prior year, the firm earned $3.58 earnings per share. Jazz Pharmaceuticals’s revenue was up 14.6% compared to the same quarter last year. As a group, analysts anticipate that Jazz Pharmaceuticals PLC will post 14.13 earnings per share for the current year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Read More: What is an overbought condition?

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.